Logo image of SLNO

SOLENO THERAPEUTICS INC (SLNO) Stock Fundamental Analysis

NASDAQ:SLNO - US8342033094 - Common Stock

71.9 USD
+2.13 (+3.05%)
Last: 9/8/2025, 12:20:33 PM
Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to SLNO. SLNO was compared to 541 industry peers in the Biotechnology industry. SLNO scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. SLNO does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year SLNO has reported negative net income.
In the past year SLNO has reported a negative cash flow from operations.
SLNO had negative earnings in each of the past 5 years.
SLNO had a negative operating cash flow in each of the past 5 years.
SLNO Yearly Net Income VS EBIT VS OCF VS FCFSLNO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50M -100M -150M

1.2 Ratios

SLNO has a Return On Assets (-54.49%) which is in line with its industry peers.
With a Return On Equity value of -75.41%, SLNO perfoms like the industry average, outperforming 54.90% of the companies in the same industry.
Industry RankSector Rank
ROA -54.49%
ROE -75.41%
ROIC N/A
ROA(3y)-55.18%
ROA(5y)-58.08%
ROE(3y)-109.68%
ROE(5y)-111.38%
ROIC(3y)N/A
ROIC(5y)N/A
SLNO Yearly ROA, ROE, ROICSLNO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -100 -200 -300 -400

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for SLNO so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
SLNO Yearly Profit, Operating, Gross MarginsSLNO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -500 -1K -1.5K -2K -2.5K

More info and screens

5

2. Health

2.1 Basic Checks

The number of shares outstanding for SLNO has been increased compared to 1 year ago.
SLNO has more shares outstanding than it did 5 years ago.
The debt/assets ratio for SLNO is higher compared to a year ago.
SLNO Yearly Shares OutstandingSLNO Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M
SLNO Yearly Total Debt VS Total AssetsSLNO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

2.2 Solvency

An Altman-Z score of 22.03 indicates that SLNO is not in any danger for bankruptcy at the moment.
The Altman-Z score of SLNO (22.03) is better than 92.79% of its industry peers.
A Debt/Equity ratio of 0.21 indicates that SLNO is not too dependend on debt financing.
The Debt to Equity ratio of SLNO (0.21) is worse than 68.76% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.21
Debt/FCF N/A
Altman-Z 22.03
ROIC/WACCN/A
WACCN/A
SLNO Yearly LT Debt VS Equity VS FCFSLNO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M 200M

2.3 Liquidity

A Current Ratio of 15.13 indicates that SLNO has no problem at all paying its short term obligations.
With an excellent Current ratio value of 15.13, SLNO belongs to the best of the industry, outperforming 90.39% of the companies in the same industry.
SLNO has a Quick Ratio of 15.01. This indicates that SLNO is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 15.01, SLNO belongs to the top of the industry, outperforming 90.02% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 15.13
Quick Ratio 15.01
SLNO Yearly Current Assets VS Current LiabilitesSLNO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

More info and screens

1

3. Growth

3.1 Past

SLNO shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -69.67%.
EPS 1Y (TTM)-69.67%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%84.21%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, SLNO will show a very strong growth in Earnings Per Share. The EPS will grow by 51.17% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y75.22%
EPS Next 2Y62.05%
EPS Next 3Y51.17%
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
SLNO Yearly Revenue VS EstimatesSLNO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2025 2026 2027 200M 400M 600M
SLNO Yearly EPS VS EstimatesSLNO Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 0 -50 -100 -150

More info and screens

3

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for SLNO. In the last year negative earnings were reported.
Based on the Price/Forward Earnings ratio of 26.96, the valuation of SLNO can be described as expensive.
SLNO's Price/Forward Earnings ratio is rather cheap when compared to the industry. SLNO is cheaper than 91.50% of the companies in the same industry.
Compared to an average S&P500 Price/Forward Earnings ratio of 22.66, SLNO is valued at the same level.
Industry RankSector Rank
PE N/A
Fwd PE 26.96
SLNO Price Earnings VS Forward Price EarningsSLNO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
SLNO Per share dataSLNO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 -4

4.3 Compensation for Growth

SLNO's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as SLNO's earnings are expected to grow with 51.17% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y62.05%
EPS Next 3Y51.17%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for SLNO!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

SOLENO THERAPEUTICS INC

NASDAQ:SLNO (9/8/2025, 12:20:33 PM)

71.9

+2.13 (+3.05%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-06 2025-08-06/amc
Earnings (Next)11-04 2025-11-04/amc
Inst Owners105.59%
Inst Owner Change3.99%
Ins Owners1.45%
Ins Owner Change-13.48%
Market Cap3.82B
Analysts86.25
Price Target120.97 (68.25%)
Short Float %12.19%
Short Ratio4.14
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)40.18%
Min EPS beat(2)-0.42%
Max EPS beat(2)80.77%
EPS beat(4)1
Avg EPS beat(4)-28.52%
Min EPS beat(4)-186.49%
Max EPS beat(4)80.77%
EPS beat(8)2
Avg EPS beat(8)-30.55%
EPS beat(12)5
Avg EPS beat(12)-17.7%
EPS beat(16)8
Avg EPS beat(16)-9.16%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)3.53%
PT rev (3m)10.15%
EPS NQ rev (1m)106.1%
EPS NQ rev (3m)103.77%
EPS NY rev (1m)67.05%
EPS NY rev (3m)65.1%
Revenue NQ rev (1m)30.07%
Revenue NQ rev (3m)475.54%
Revenue NY rev (1m)29.3%
Revenue NY rev (3m)207.76%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 26.96
P/S 117.02
P/FCF N/A
P/OCF N/A
P/B 15.91
P/tB 16.31
EV/EBITDA N/A
EPS(TTM)-4.14
EYN/A
EPS(NY)2.67
Fwd EY3.71%
FCF(TTM)-1.59
FCFYN/A
OCF(TTM)-1.59
OCFYN/A
SpS0.61
BVpS4.52
TBVpS4.41
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -54.49%
ROE -75.41%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-55.18%
ROA(5y)-58.08%
ROE(3y)-109.68%
ROE(5y)-111.38%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.1
Health
Industry RankSector Rank
Debt/Equity 0.21
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 10.53%
Cap/Sales 0.65%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 15.13
Quick Ratio 15.01
Altman-Z 22.03
F-Score3
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)3.83%
Cap/Depr(5y)2.6%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-69.67%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%84.21%
EPS Next Y75.22%
EPS Next 2Y62.05%
EPS Next 3Y51.17%
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-165.04%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-283.29%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-282.33%
OCF growth 3YN/A
OCF growth 5YN/A